PLX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
PLX is a buy right now. The chart is in a bullish uptrend (SMA_5 > SMA_20 > SMA_200), price is holding above the pivot (2.057), and options positioning is strongly call-skewed (very low put/call ratios). While the latest quarter showed softer YoY growth (revenue and earnings down) and there’s no fresh news catalyst this week, the current technical setup and sentiment data favor upside follow-through from current levels (~2.11), which fits an impatient “buy now” approach.
Trend is bullish: moving averages are stacked positively (SMA_5 > SMA_20 > SMA_200), indicating an established uptrend. Momentum is positive but cooling: MACD histogram is above zero (0.00352) but contracting, suggesting upside continues but may be slower near-term. RSI_6 at 55.35 is neutral-to-slightly-bullish (not overbought). Key levels: pivot support 2.057; S1 1.996. Immediate resistance is tight overhead at R1 2.118 (price ~2.11), then R2 2.156—so a break above ~2.12 would be the next technical confirmation. Pattern-based projection indicates a favorable month bias (estimated +6.56% next month).
Bullish technical structure (SMA stack) with price above pivot support; strong call-skewed options positioning (very low put/call); low IV percentile/rank suggests options are priced calmly (often consistent with constructive sentiment); pattern-based stats show a positive bias over the next month (+6.56% estimate).
No news/events this week to act as a near-term catalyst; momentum is positive but decelerating (MACD histogram contracting) and price is very near resistance (~2.118), which can cap immediate upside unless broken; latest quarterly results show YoY declines in revenue, net income, and EPS, which can limit multiple expansion without a growth re-acceleration.
2025/Q3: Revenue $17.851M (-0.60% YoY), Net Income $2.355M (-27.22% YoY), EPS $0.03 (-25.00% YoY). Gross margin was 53.37% (roughly flat YoY). Overall: profitability and EPS weakened YoY while margins held up, implying the main issue is growth/scale rather than unit economics.
Recent analyst activity (relevant to PLX): H.C. Wainwright reiterated Buy but lowered the price target to $12 from $15 after Q3, citing a more gradual ramp in Elfabrio sales/royalties. That’s a positive “pros still bullish” signal, but the target cut highlights a slower fundamental ramp as the main bear point. (Other listed updates reference Pluxee and are not applicable to Protalix/PLX.) Wall Street pros: maintains a Buy stance and sees substantial upside vs ~$2.11; cons: reduced near-term expectations tied to slower commercial/royalty ramp. Ownership/trading: hedge funds neutral; insiders neutral. Politicians/congress: no recent congress trading data available.
